Pier Luigi Zinzani

Pier Luigi Zinzani, MD, PhD is Professor of Hematology and Director of the Institute of Hematology "L. e A. Seràgnoli" at the University of Bologna and IRCCS University Hospital, one of Europe's leading hematology centers. He is internationally recognized as one of the world's foremost experts in T-cell lymphomas and is a key contributor to the ECHELON-2 trial — the landmark phase III study published in The Lancet (2019) demonstrating that brentuximab vedotin plus CHP (A+CHP) significantly improved progression-free and overall survival compared with standard CHOP in patients with previously untreated CD30-positive peripheral T-cell lymphoma (PTCL), resulting in FDA and EMA approval of A+CHP as the new frontline standard for this disease. Dr. Zinzani has authored more than 600 peer-reviewed publications covering the full spectrum of mature lymphoid neoplasms, with particular depth in cutaneous T-cell lymphoma, natural killer/T-cell lymphoma, anaplastic large cell lymphoma, and aggressive B-cell lymphomas. He serves as president of the Italian Lymphoma Foundation (FIL), leading a national cooperative group network that has generated numerous pivotal trials in T-cell and B-cell lymphoma. He is also a recognized authority on novel agents in relapsed lymphoma, including PI3K inhibitors, PD-1 checkpoint inhibitors, and antibody-drug conjugates.